OKYO Pharma
Tracked across 4 events · 44 articles · First seen May 19, 2026 · Last active Jul 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: OKYO Pharma>>> expanded its Scientific Advisory Board with the appointment of Marta Sacchetti>>> to strengthen its expertise in neuro-inflammatory corneal diseases and advance its clinical programs for Urgoskin.
May 19, 2026 · 7 articles
Business
Impact: OKYO Pharma is the subject of the announcement, participating in the symposium to present its clinical developments.
Jul 07, 2026 · 6 articles
Regulatory
Impact: OKYO Pharma received positive FDA feedback validating its clinical path for urcosimod, de-risking the program and supporting advancement into a global Phase 3 trial. This milestone could enhance the company's valuation and prospects.
Jul 08, 2026 · 9 articles
Business
Impact: OKYO Pharma is the subject of insider buying, indicating management confidence. The company is preparing for a Phase 3 trial of urcosimod for NCP.
Jul 21, 2026 · 22 articles
Flavio Mantelli
cmo
↔
OKYO Pharma
Flavio Mantelli is the Chief Medical Officer of OKYO Pharma, where he oversees t
ERGEN INTELLIGENCE
Track OKYO Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard